Skip to main content

Table 3 Average TBF and [18F]FLT V T values of all the lesions as assessed at the three time points: baseline, 7 days post-therapy and 28 days post-therapy

From: Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor

  Baseline 7 days post-therapy 28 days post-therapy
Patients TBF
1 0.46 0.40 0.44
2 0.60 0.85 0.86
3 0.47 0.58 0.39
4 0.54 0.58 0.82
5 0.32 –* 0.27
6 0.49 0.35 0.32
Patients [18F]FLT V T
1 5.69 3.63 3.21
2 4.89 2.75 3.30
3 7.62 2.83 3.21
4 4.75 3.71 3.20
5 5.02 4.17 3.26
6 4.20 2.70 2.54
  1. *TBF data for patient 5 was unavailable